8 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| 2025 | $7M | -$3M | 14.6% | -39.9% | -34.6% | -32.3% | -$2M | — | $2M |
| 2024 | $10M | -$2M | 13.6% | -16.5% | -19.2% | -15.3% | -$2M | — | $3M |
| 2023 | $10M | -$3M | 13.6% | -26.5% | -27.2% | -23.1% | -$2M | — | — |
| 2022 | $11M | -$355966 | 11.5% | -2.7% | -5.3% | -4.1% | $551822 | — | — |
| 2021 | $13M | $751571 | 17.0% | 7.9% | 10.5% | 7.8% | $5999 | — | $2M |
| 2020 | $11M | $1M | 15.1% | 11.2% | 16.4% | 10.8% | $131059 | — | $3M |
| 2019 | $126955 | -$246469 | 44.0% | -217.2% | -22.0% | -20.0% | -$230090 | — | $859076 |
| 2018 | $212328 | $26454 | 13.5% | 28.2% | 1.7% | 1.6% | -$234459 | — | $1M |
| Quarter | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| Jun '26 | $76156 | -$286451 | 17.0% | -370.8% | -3.7% | -3.3% | -$422741 | — | $1M |
| Mar '26 | $22842 | -$543575 | -3.5% | -2366.2% | -6.7% | -6.0% | -$147996 | — | — |
| Dec '25 | $483760 | -$1M | -0.8% | -213.5% | -12.0% | -11.2% | $960085 | — | $2M |
| Sep '25 | $3M | -$708991 | 14.8% | -27.6% | -10.4% | -9.3% | -$1M | — | — |
| Jun '25 | $2M | -$616172 | 16.3% | -27.0% | -8.2% | -6.5% | -$759366 | — | — |
| Mar '25 | $2M | -$623327 | 16.1% | -28.9% | -8.0% | -6.6% | -$833124 | — | — |
| Dec '24 | $3M | -$348319 | 12.3% | -16.5% | -4.2% | -3.3% | $215181 | — | $3M |
| Sep '24 | $3M | -$1M | 12.4% | -50.9% | -14.3% | -12.2% | -$2M | — | — |
| Jun '24 | $2M | $199104 | 14.6% | 13.1% | 2.1% | 1.8% | -$674108 | — | — |
| Mar '24 | $2M | -$103757 | 15.3% | -3.3% | -1.1% | -0.9% | -$59098 | — | — |
| Dec '23 | $2M | $308463 | 11.7% | 11.3% | 3.2% | 2.7% | -$783463 | — | — |
| Sep '23 | $3M | -$3M | 13.9% | -99.0% | -28.0% | -22.8% | -$1M | — | — |
| Jun '23 | $3M | -$259251 | 13.2% | -10.6% | -4.6% | -3.3% | -$38179 | — | — |
| Mar '23 | $2M | -$69066 | 15.5% | -2.1% | -1.1% | -0.8% | -$116620 | — | — |
| Dec '22 | $3M | -$156969 | 11.9% | -4.3% | -2.4% | -1.8% | $513883 | — | — |
| Sep '22 | $3M | -$77401 | 11.6% | -2.5% | -1.2% | -1.0% | $305231 | — | — |
| Jun '22 | $2M | -$138662 | 10.6% | -5.6% | -2.0% | -1.7% | -$197262 | — | — |
| Mar '22 | $3M | $17066 | 11.8% | 1.1% | 0.2% | 0.2% | -$70030 | — | $2M |
| Dec '21 | $3M | $89243 | 14.7% | 6.2% | 1.2% | 0.9% | $481728 | — | $2M |
| Sep '21 | $4M | $295322 | 19.8% | 10.4% | 4.2% | 3.0% | $315459 | — | $2M |
How the market has priced BGLC against its own fundamentals since 2023-07 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, BioNexus Gene Lab Corp's revenue has declined 8.2% per year. These are computed facts, not advice.
As of FY2025, BioNexus Gene Lab Corp reported — of total debt against $2M of cash.
In FY2025, gross margin was 14.6%, operating margin -39.9%, and net margin -40.2%.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.